Vimseltinib’s effect on P-glycoprotein inhibition in healthy men

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This early-phase study investigates how vimseltinib affects the pharmacokinetics of a P-gp substrate (dabigatran) in healthy male volunteers. It is a 21-day, interventional trial that co-administers vimseltinib and dabigatran to observe drug interactions. The trial will assess safety, tolerability, and how the drugs interact at the body’s absorption, distribution, metabolism, and excretion levels. Participants must be generally healthy, within specific BMI and lab criteria, and able to comply with study procedures. The study is led by Deciphera Pharmaceuticals with Dr. Vince Clinical Research in Overland Park, KS.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Participants are in good general health, as required by the protocol and as determined by Principal Investigator.
2. Body mass index (BMI) from greater than or equal to (≥) 18 to less than or equal to ≤ 32 kilogram per square meter (kg/m\^2).
3. Adequate organ function and blood and urine tests, as required by the protocol and as determined by Principal Investigator.

Exclusion Criteria:

1. History or presence of clinically significant diseases of the neurological, dermatological, renal, hepatic, gastrointestinal, cardiovascular, or musculoskeletal systems or history or presence of clinically significant psychiatric, immunological, endocrine, or metabolic disease as determined by Principal Investigator.
2. Unwilling or unable to comply with the requirements of the protocol.
3. Determined by Principal Investigator to be unsuitable to participate in the study for any other reason.

Where it's running

• Dr. Vince Clinical Research
  Overland Park, Kansas, United States Recruiting

Study contacts

• Study coordinator: Clinical Team
• Email: clinicaltrials@deciphera.com
• Phone: 888-724-3274

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Real-world experience with vimseltinib for tenosynovial giant cell tumor

  This registry will collect real-world information about how people with TGCT take vimseltinib and how it affects their symptoms and quality of life.

  Recruiting Deciphera Pharmaceuticals, LLC · Wilmington, North Carolina · NCT07075471

• Evaluating Vimseltinib for Chronic Graft-Versus-Host Disease in Adults

  This study is testing if a new medication called vimseltinib can help adults with tough cases of chronic graft-versus-host disease feel better after other treatments haven't worked.

  Recruiting at 26 sites Phase 2 Deciphera Pharmaceuticals, LLC · Duarte, California and 25 other locations · NCT06619561

• DCC-2812 in advanced kidney, bladder, and castration-resistant prostate cancers

  This trial will test whether the oral drug DCC-2812 is safe and shows early signs of benefit for people with advanced kidney (renal cell), bladder (urothelial), or castration-resistant prostate cancer.

  Recruiting at 8 sites Phase 1 Deciphera Pharmaceuticals, LLC · Boston, Massachusetts and 7 other locations · NCT06966024

• Evaluating DCC-3009 for treating gastrointestinal stromal tumors

  This study is testing a new treatment called DCC-3009 for people with gastrointestinal stromal tumors to see if it is safe and effective, either on its own or with other cancer therapies.

  Recruiting at 10 sites Phase 1/2 Deciphera Pharmaceuticals, LLC · Scottsdate, Arizona and 9 other locations · NCT06630234

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.